Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - betahistine dihydrochloride, quantity: 16 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; mannitol; citric acid monohydrate; purified talc - meniere's syndrome as defined by the following core symptoms: - vertigo (with nausea/vomiting): - hearing loss (hardness of hearing): - tinnitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd - betahistine dihydrochloride -

Ireland - English - HPRA (Health Products Regulatory Authority)

abbott healthcare products ltd - betahistine hydrochloride - tablets - 8 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

abbott healthcare products ltd - betahistine hydrochloride - tablets - 16 milligram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - betahistine dihydrochloride - oral tablet - 8mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbott laboratories (m) sdn. bhd. - (refer beta1697) -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbott laboratories (m) sdn. bhd. - betahistine dihydrochloride -

Ireland - English - HPRA (Health Products Regulatory Authority)

viatris healthcare limited - betahistine hydrochloride - tablet - antivertigo preparations; betahistine

Ireland - English - HPRA (Health Products Regulatory Authority)

viatris healthcare limited - betahistine hydrochloride - tablet - antivertigo preparations; betahistine

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - betahistine dihydrochloride 16mg;   - tablet - 16 mg - active: betahistine dihydrochloride 16mg   excipient: citric acid monohydrate colloidal silicon dioxide mannitol microcrystalline cellulose purified talc